Valuation: Center Laboratories, Inc.

Market Cap 29.41B 912M 789M 738M 674M 1.27B 86.94B 1.29B 8.65B 3.39B 43.49B 3.42B 3.35B 145B P/E 2024
-28.2x
P/E 2025 3.64x
Enterprise Value 33.45B 1.04B 898M 839M 767M 1.44B 98.88B 1.47B 9.84B 3.86B 49.47B 3.89B 3.81B 165B EV / Sales 2024
22.3x
EV / Sales 2025 23.1x
Free-Float
72.62%
Yield 2024
1.71%
Yield 2025 4.2%
13/05 Center Laboratories says Jan-Mar net profit at T$1.97 bln RE
13/05 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
14/04 Center Laboratories, Inc. announces Annual dividend, payable on September 11, 2026 CI
01/04 WuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders. CI
03/03 Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
14/01 WuXi XDC Cayman Inc. proposed to acquire 60% stake in BioDlink International Company Limited from a group of shareholders for HKD 1.9 billion. CI
12/11 Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
13/08/25 Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/06/25 Tranche Update on Center Laboratories, Inc.'s Equity Buyback Plan announced on April 9, 2025. CI
09/06/25 Center Laboratories, Inc.'s Equity Buyback announced on April 9, 2025, has expired with 9,909,000 shares, representing 1.38% for TWD 383.08 million. CI
12/05/25 Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/05/25 Medeon Biodesign, Inc. cancelled the transaction announced on February 29, 2024 CI
09/04/25 Center Laboratories, Inc. announces an Equity Buyback for 20,000,000 shares, representing 2.76% for TWD 9,141.18 million. CI
1 day+0.77%
1 week+2.34%
Current month+4.37%
1 month+1.16%
3 months+3.82%
6 months-0.76%
Current year-5.29%
1 week 38.65
Extreme 38.65
39.4
1 month 36.6
Extreme 36.6
39.5
Current year 36.6
Extreme 36.6
51.4
1 year 33.1
Extreme 33.1
51.4
3 years 29.12
Extreme 29.123639
56.72
5 years 29.12
Extreme 29.123639
58.79
10 years 20.99
Extreme 20.988436
64.21
Manager TitleAgeSince
Chief Executive Officer - 03/08/1998
Director of Finance/CFO - 08/12/2022
Chief Tech/Sci/R&D Officer - 01/07/1983
Director TitleAgeSince
Chairman - 30/11/2022
Director/Board Member 61 14/06/2010
Director/Board Member - 14/06/2010
Change 5-day change 1-year change 3-year change Capi.($)
+0.77%+2.34%+9.08%-20.87% 912M
+3.90%+9.86%+96.91%+136.30% 1,098B
+0.99%+2.91%+51.05%+52.06% 631B
+0.78%+1.17%+25.21%+63.74% 438B
+1.58%+4.80%+51.42%+39.79% 368B
+0.65%+1.85%+34.81%+39.99% 298B
+0.79%+4.26%+9.78%+7.42% 251B
+1.52%+10.12%+44.75%+59.20% 226B
+0.34%+1.27%-5.23%-50.94% 209B
-0.11%+1.46%+11.43%+66.32% 165B
Average +1.12%+2.91%+32.92%+39.30% 368.53B
Weighted average by Cap. +1.80%+4.82%+52.18%+68.52%

Financials

2024 2025
Net sales 1.62B 50.14M 43.4M 40.57M 37.08M 69.87M 4.78B 70.97M 476M 187M 2.39B 188M 184M 7.97B 1.52B 46.99M 40.68M 38.02M 34.75M 65.48M 4.48B 66.51M 446M 175M 2.24B 176M 173M 7.47B
Net income -1.1B -34.2M -29.61M -27.68M -25.29M -47.67M -3.26B -48.41M -325M -127M -1.63B -128M -126M -5.44B 9.32B 289M 250M 234M 214M 403M 27.56B 409M 2.74B 1.08B 13.79B 1.08B 1.06B 45.91B
Net Debt 4.48B 139M 120M 112M 103M 193M 13.24B 197M 1.32B 517M 6.62B 521M 510M 22.06B 4.04B 125M 108M 101M 92.62M 175M 11.94B 177M 1.19B 466M 5.98B 470M 460M 19.9B
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
10/08/26 TWD 39.40 +0.77% 2,895,762
07/08/26 TWD 39.10 +0.90% 2,022,459
06/08/26 TWD 38.75 -1.02% 1,663,049
05/08/26 TWD 39.15 +0.51% 3,354,739
04/08/26 TWD 38.95 +1.17% 3,012,874
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. 4123 Stock